Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Ireland
Regulatory Approval:
N/A
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Vyxeos (daunorubicin and cytarabine liposome) is a fixed-ratio combination chemotherapy approved by the FDA for the treatment of adults and pediatric patients 1 year and older with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Vyxeos encapsulates daunorubicin and cytarabine together in a liposomal formulation at a fixed 1:5 molar ratio, which has been shown to synergistically target leukemic cells more effectively than the same drugs given separately, particularly in these higher-risk AML subtypes.
Vyxeos is intended for AML patients with a history of prior chemotherapy or radiation for another cancer (therapy-related AML), or those whose AML shows myelodysplasia-related changes — both associated with a poorer prognosis using standard chemotherapy regimens.
Induction dosing is daunorubicin 44 mg/m² plus cytarabine 100 mg/m² administered intravenously over 90 minutes on Days 1, 3, and 5 (Days 1 and 3 for subsequent induction cycles if needed). Consolidation dosing is daunorubicin 29 mg/m² plus cytarabine 65 mg/m² on Days 1 and 3.
Boxed Warning — Vyxeos: Do not interchange Vyxeos with other daunorubicin and/or cytarabine-containing products. Vyxeos has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify the drug name and dose prior to preparation and administration to avoid dosing errors.
Serious and fatal hemorrhagic events have been reported, related to prolonged thrombocytopenia associated with treatment.
Vyxeos contains an anthracycline component and is not recommended in patients with pre-existing cardiac impairment due to cumulative dose-related cardiotoxicity risk.
Hypersensitivity reactions have been reported, and extravasation can cause tissue necrosis; the infusion site should be monitored closely.
Vyxeos may cause fetal harm. Effective contraception should be used during treatment and for a period after the final dose, as advised by the treating physician.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Vyxeos is manufactured and marketed by Jazz Pharmaceuticals. It is sourced through authorized distribution channels for patients seeking named-patient import into India.
Patients typically need a valid prescription from a treating hematologist-oncologist confirming diagnosis of therapy-related AML or AML-MRC. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved therapy for high-risk AML subtypes, Vyxeos is sourced through authorized channels and imported under GDP-compliant, cold-chain logistics to preserve product quality throughout transit.
NPP sources Vyxeos directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Vyxeos requires refrigerated storage at 2°C to 8°C in an upright position, protected from light. NPP maintains a continuous, monitored cold chain throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile cold-chain logistics to the patient's city.
Patients across India can access Vyxeos through NPP's regulated import pathway, with hematology-oncology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support hematology-oncology care coordination and documentation for Vyxeos access.
Delhi's major hospitals assist patients with prescription support and documentation for Vyxeos.
Bangalore's specialist network offers access coordination for eligible AML patients seeking Vyxeos.
Chennai-based hematology specialists coordinate Vyxeos access alongside comprehensive AML care.
Hyderabad's care institutions support patients pursuing Vyxeos therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Vyxeos.
Pune-based specialists assist with prescription support and Vyxeos treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Vyxeos.
Kochi's specialist units assist patients with the documentation needed for Vyxeos access.
Chandigarh's care centers support Vyxeos treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Vyxeos access process.
Lucknow-based centers assist patients pursuing Vyxeos therapy.
Bhubaneswar's institutions support access to Vyxeos for eligible patients.
Guwahati's specialists help coordinate Vyxeos access for patients across the Northeast.
Patients in other cities across India can also access Vyxeos through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 15 September 2026
Sources: FDA
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
